Article | 2026 ASRS Meeting
Does Timing Matter in Gene Therapy for nAMD?
Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.







